RE:RE:RE:RE:OTC Short Interest UP-DateBalain, i'm thinking that PLI will be able to strike some deals on 4050, especially IPF, with current phase 2 data. I mean it is showing results better than existing standard of care drugs, even if not placebo controlled. Perhaps the upfront cash component may not be as high as people would hope but follow-on milestone payments and big cash payments when the drug is approved along with follow-on royalties could work.
A couple of regional deals on IPF and a couple of partnership deals on plasminogen and other plasma proteins should address the cash shortfall until PLI is cashflow positive (late 2018 -- early 2019). We can't overlook the possibility of a voucher. Hopefully, we will hear from the FDA on pediatric designation and priority review in September. I fully agree that unless such deals are closed or vouchers obtained, the sp will languish and get clobbered once again if another equity financing is required.